Hepatitis B virus resistance to tenofovir: fact or fiction?

A synthesis of the evidence to date

Jolynne Mokaya[1], Anna L McNaughton[1], Phillip A Bester[2], Dominique Goedhals[2], Eleanor Barnes [1,3,4], Brian D Marsden[5,6], Philippa C Matthews[1,4,7*]

[1] Nuffield Department of Medicine, Medawar Building, South Parks Road, Oxford OX1 3SY, UK

[2] Division of Virology, National Health Laboratory Service/University of the Free State, Bloemfontein, South Africa

[3] Department of Hepatology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK

[4] National Institutes of Health Research Health Informatics Collaborative, NIHR Oxford Biomedical Research Centre, The Joint Research Office, Second Floor, OUH Cowley, Unipart House Business Centre, Garsington Road Oxford OX4 2PG

[5] Structural Genomics Consortium, University of Oxford, Oxford, UK

[6] Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Roosevelt Drive, Headington, Oxford, UK

[7] Department of Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK

***Corresponding author**: philippa.matthews@ndm.ox.ac.uk; **Phone:** 01865 271973

SHORT RUNNING TITLE: Evidence of hepatitis B virus resistance to tenofovir

28 **ABBREVIATIONS**

29 - 3TC - lamivudine
30 - ADV – Adefovir
31 - ART – antiretroviral therapy
32 - cccDNA – covalently closed circular DNA
33 - CHB – chronic hepatitis B virus infection
34 - ETV – entecavir (ETV)
35 - HBsAg – Hepatitis B surface antigen
36 - HBV – Hepatitis b virus
37 - HIV – human immunodeficiency virus
38 - LdT – telbivudine
39 - NA – Nucleos(t)ide analogue
40 - RAM – Resistance Associated Mutation
41 - RT – reverse transcriptase
42 - TAF – tenofovir alafenamide
43 - TDF – tenofovir disoproxil fumarate
44 - TFV – tenofovir (the active component of both TAF and TDF)
45 - YMDD – tyrosine methionine aspartate aspartate motif in HBV RT

46

47

ABSTRACT

Background: Tenofovir (TFV) is a widely used antiviral treatment for chronic hepatitis B virus (HBV) infection. There is a high genetic barrier to the selection of TFV resistance-associated mutations (RAMs), but the distribution and clinical significance of TFV RAMs are not well understood, and the topic remains contentious. We here present assimilated evidence for putative TFV RAMs with the aims of cataloguing and characterising mutations that have been reported, and starting to develop insights into the mechanisms of resistance and potential clinical significance.

Methods: We carried out a systematic literature search in PubMed to identify clinical, *in vitro* and *in silico* evidence of TFV resistance. The structure of HBV reverse transcriptase (RT) has not been solved; we therefore compared HBV RT to the crystal structure for HIV RT to map the likely sites of RAMs.

Results: We identified a 'long-list' of 37 putative TFV RAMs in HBV RT, occurring within and outside sites of enzyme activity, some of which can be mapped onto a homologous HIV RT structure. Based on quality and quantity of supporting data, we generated a 'short-list' of nine sites that are supported by the most robust evidence. Most resistance arises as a result of suites of multiple RAMs. Other factors including adherence, viral load, HBeAg status, HIV coinfection and NA dosage may also influence viraemic suppression.

Conclusion: There is emerging evidence for polymorphisms that may reduce susceptibility to TVF**.** A better understanding of HBV drug resistance is imperative to optimise approaches to public health elimination targets.

69 **INTRODUCTION**

70 Nucleot(s)ide analogues (NA) are the most widely used antiviral treatments for chronic HBV
71 (CHB) infection (1), with tenofovir (TFV) being safe, cheap, and widely available agent. NA
72 agents inhibit the action of HBV reverse transcriptase (RT), acting as DNA chain terminators.
73 NA therapy can be effective in suppressing HBV viraemia, thus reducing the risks of
74 inflammation, fibrosis and hepatocellular carcinoma (HCC) as well as lowering the risk of
75 transmission (1). However, NAs are not curative due to the persistent intracellular hepatic
76 reservoir of HBV covalently closed circular DNA (cccDNA). Long-term administration is
77 therefore typically required (2), with a potential risk of selection of resistance associated
78 mutations (RAMs) in the virus (3,4). RAMs are mostly likely to arise in the context of high viral
79 replication, arising as a result of the error prone RT enzyme (1).

80

81 Lamivudine (3TC), telbivudine (LdT) and adefovir (ADV) have been phased out of use in HBV
82 management, mainly due to the predictable selection of RAMs over time (1). The best
83 recognised 3TC RAM arises at RT-M204, representing the second position of the tyrosine-
84 methionine-aspartate-aspartate ('YMDD') motif in viral RT (1,4). Resistance to TFV,
85 formulated either as tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)
86 (**Suppl Fig 1)**, remains controversial. Unlike other NAs, TFV has a high genetic barrier to
87 resistance (1), corroborated by studies that report no resistance after many years of treatment
88 (5). An on-line tool, 'geno2pheno hbv', lists only one position (RT N236T) in association with
89 reduced TFV susceptibility, while other reports also include A181T/V (6). However, there are
90 emerging reports of a wider range of amino acid substitutions that are associated with reduced
91 TFV sensitivity, described in both treatment-experienced and treatment-naïve individuals with
92 CHB (7,8).

93

94 There is some degree of homology between the sequence, structure and function of HIV and
95 HBV RT enzymes, explaining why certain NAs are active against both viruses (9). Although
96 no crystal structure has been resolved for HBV RT, some studies have modelled this enzyme

97 based on the HIV crystal structure (9–11), suggesting that insights into HBV drug resistance
98 mechanisms might be inferred from what is known about HIV.
99
100 A better understanding of the role of NA therapy in driving HBV elimination at a population
101 level is crucial to underpin efforts to move towards international targets for elimination by the
102 year 2030 (3,12). For populations in which HIV and HBV are both endemic, as exemplified by
103 many settings in sub-Saharan Africa, there are particular concerns about drug resistance in
104 HBV, given the widespread population exposure to TDF as a component of first-line
105 antiretroviral therapy (ART) for HIV (3). In order to progress towards these targets, many more
106 people will need to be treated in the decade ahead.
107
108 We have therefore undertaken a systematic approach to assimilate the current evidence for
109 the development of clinical or virological HBV breakthrough during TFV therapy. The evidence
110 on this topic is not currently sufficiently advanced to underpin definitive conclusions regarding
111 specific genetic signatures that underpin TVF resistance, or the extent to which these are
112 significant in clinical practice. However, we add to the field by providing a comprehensive
113 summary of relevant publications, together with a quality appraisal of the evidence. We used
114 this process to assimilata a 'long-list' (all putative TFV RAMs) and a 'short-list' (a refined
115 catalogue containing only the polymorphisms most robustly supported by existing data). We
116 highlight gaps in the existing data and the urgent need for more research.
117

118 **METHODS**

119 **Search strategy and quality appraisal**

120 We undertook a systematic search of PubMed and Scopus in February 2019, using PRISMA
121 criteria (**Suppl Fig 2**). We used the search terms ("*Hepatitis B virus" [Mesh] OR "hepatitis b"*
122 *OR HBV*) AND (*Tenofovir OR TDF* OR *TAF* OR *"Tenofovir alafenamide"* OR "*Tenofovir*
123 *Disoproxil Fumarate*") *AND* (*resista* OR drug muta* OR DRMs OR RAMs OR viremia OR*
124 *replica**). We reviewed the titles and abstracts matching the search terms and included those

125 reporting virological HBV breakthrough after exposure to TFV, only including studies that
126 presented original data and had undergone peer review. We used the Joanna Briggs Institute
127 Critical Appraisal tool checklist to assess for quality of case reports (13). For assessment of
128 quantitative studies, we used the BMJ adapted Quality Assessment Tool for Quantitative
129 Studies (14).
130
131 **Appraisal of putative sites of drug resistance**
132 Recognising that there is sparse and varied evidence to support TDF RAMs, we divided our
133 data into two categories. First, we generated a 'long list' of all polymorphisms that have been
134 reported in association with TFV resistance, to summarise all the available data in the most
135 inclusive way. We then refined this into a 'short list' including just those sites supported by the
136 most robust evidence, based on reporting in ≥2 studies, and a combination of *in vivo* and *in*
137 *vitro* evidence.
138
139 **Sequence analysis**
140 To assess similarity between HIV and HBV RT, we downloaded HIV and HBV reference
141 sequences from a publicly available repositories: HIV sequence database (15) and Hepatitis
142 B Virus Database (16). We aligned amino acid RT sequences using MAFFT version 7 (17).
143 The alignment illustrates regions of similarity and differences between HIV and HBV RT. We
144 obtained RAMs associated with HIV resistance to TFV from Stanford University HIV drug
145 resistance database (18).
146
147 **Structural analysis**
148 The crystal structure for HBV RT has not been solved, However, the enzyme is homologous
149 to HIV RT. In order to further assess the relevance of sites included in a 'long list' of all
150 polymorphisms, we therefore considered evidence for a mechanistic influence by mapping
151 HBV RAMs onto a previously solved crystal structure of HIV RT (PDB code 3dlk) (19) using
152 ICM [http://www.molsoft.com/icm_pro.html].

153

154 **RESULTS**

155 **Nature and quality of the evidence identified**

156 We identified 15 studies that met our search criteria. Although some studies used hybrid
157 methods, we classified them broadly as seven studies arising from clinical case reports
158 (7,8,20–24), (one of these also presented in vitro evidence for drug resistance (8)), four from
159 *in vitro* studies (25–27) and four from longitudinal studies of CHB (with or without HIV
160 coinfection) (28–31). Studies were from Asia (7,8,20,22,27), Australia (31), Europe
161 (21,24,26,28–30) and USA (23,25,32). Despite the high prevalence of HBV infection in Africa,
162 and the widespread use of TFV for HIV across this continent, it is striking that no African data
163 have been published to date. Eight studies reported HBV genotypes, representing genotypes
164 A-G (8,20,23–25,28–30,32). Metadata for individual studies are provided in **Suppl Table 1**.

165

166 A detailed quality assessment of each individual reference is included in **Suppl Table 2.**
167 Among the case reports, three were of high quality as they clearly described patients'
168 characteristics, clinical details, diagnosis, treatment and follow-up, and concluded with take
169 away lessons (20–22). Three further case reports did not describe diagnostic or assessment
170 methods (7,23,24), and one study did not describe post-intervention follow-up (8). The overall
171 quality rating for four cohort studies was strong because participants selected represented the
172 target population, characteristics of participants were clearly described, there was a clear
173 hypothesis for the study, and inclusion/exclusion criteria were specified (28–31). Two studies
174 had a weak rating because there was no description of the characteristics of participants and
175 it was not clear to what extent participants were representative of the target population (25,32).
176 Two natural experimental studies were not rated because the quality assessment questions
177 were not applicable (26,27).

178

179 **Approach to defining resistance**

180 Resistance was studied based on exposure to TDF in 13 studies and TAF in two studies; we
181 therefore refer to TFV throughout the results section. TFV resistance was determined using a
182 range of strategies, which can be summarised as follows:

183 i. A sequencing approach to identifying possible RAMs in HBV sequence isolated from
184 individuals in whom viraemia was not suppressed by TFV therapy, undertaken in
185 seven studies (7,20,22–24,28,31);
186 ii. *In vitro* assays to measure the effect of TFV on viral replication in cell lines, reported
187 by three studies (25,26,32);
188 iii. Approaches (i) and (ii) in combination, applied in four studies (8,21,29,30);
189 iv. Approach (ii) combined with an animal model, described by one study (27).

190

191 In 12/15 studies, HBV mutations were reported in association with TFV resistance or reduced
192 TFV susceptibility (8,20,21,24–30,32). In the remaining three studies, persistent viraemia was
193 reported among individuals with chronic HBV infection while on TFV but either no RAMs were
194 identified (23,31) or viral sequencing was not performed due to low viral load (22).

195

196 **Location and number of RAMs associated with TFV resistance**

197 We generated a 'long-list' of 37 different sites of polymorphism, arising both within (n=15) and
198 outside (n=22) enzymatically active sites in RT (Fig 1; **Suppl Table 3**). HBV mutations outside
199 active sites of the enzyme occurred in combination with RAMs located within active sites, with
200 the exception of A194T. Only two studies reported TFV resistance arising from the selection
201 of a single mutation, S78T and A194T (21,26). S78T was defined by sequencing HBV from
202 two individuals in whom viraemia was not suppressed by TDF, combined with *in vitro* assays
203 (21), while A194T was only defined *in vitro* (26). In all other studies, ≥2 RAMs were required
204 to confer TFV resistance (2 RAMs in four studies (25,27,28,32), 3 RAMs in one study (30), 5
205 RAMs in one study (8), and ≥8 RAMs in a further four studies (7,20,24,29)). This pattern
206 supports the high genetic barrier to selection of TFV resistance.

207

208 We narrowed the list of 37 sites down to compile a 'short-list' of TFV RAMs that have been
209 identified in ≥2 studies, regarding these sites as having the strongest evidence base (9 sites;
210 **Table 1)**. The most frequently described RAMs were L180M (20,29,30), A181T/V
211 (25,28,29,32), M204I/V (8,20,29,30), and N236T (25,28,32), which were all identified through
212 sequencing and tested in *in vitro* assay to measure the effect of TDF on viral replication in cell
213 lines. Among these, the M204 mutation (within the 'YMDD' motif) is well established in
214 association with 3TC resistance, commonly arising in combination with substitutions at
215 positions V173, L180 and A181, while N236 substitutions appear to be more specifically
216 associated with reduced susceptibility to ADV and TFV (6). Mutations at sites 177, 194 and
217 249 may also be more specific to TFV resistance, having been less clearly reported in
218 association with resistance to other agents (3,33). Polymorphisms at positions 80, 173 and
219 184 have been described as compensatory changes to allow the virus to accommodate the
220 primary drug escape substitution (6). These mutations on their own may not be sufficient to
221 mediate TVF resistance but may be a necessary compensatory contribution to combinations
222 of mutations that underpin resistance.
223
224 Some reported polymorphisms associated with drug resistance represent wild type sequence
225 in some genotypes (Y9H, F122L, H126Y, R153W/Q, F221Y, S223A, C256S, D263E, V278IV
226 and A317S), and our assimilation shows more resistance in genotype D (**Suppl Table 4**). Most
227 of these polymorphisms are located outside the active site of the enzyme, with the exception
228 of position 256. The barrier to selection of TFV resistance may therefore be lower in certain
229 genotypes, (Fig 1, **Suppl Table 4**). The same phenomenon has been described for HCV
230 resistance, in which certain sub genotypes are predicted to be intrinsically resistant to certain
231 direct acting antiviral agents due to the presence of resistance associated polymorphisms in
232 the wild type sequence (34,35).
233
234 One study assessed the replication competence and susceptibility to TFV of mutated HBV
235 clones *in vitro* and *in vivo* using mice models. The introduction of P177G and F249A mutations

236 (substitutions in active sites of the RT enzyme) in HBV clones, resulted in a reduction in their
237 susceptibility to TFV (27).
238
239 **RAMs occurring as minor quasispecies**
240 There is limited evidence for the significance of TFV RAMs occurring as minor quasispecies.
241 One study that performed ultra-deep pyrosequencing enrolled HIV/HBV co-infected
242 individuals on (or about to start) TFV-containing ART, reporting minor variants present at
243 <20% with mutations (V173, L180M, A181T/V and M204V) in 2/50 TFV naïve samples and
244 1/14 sample obtained from a TDF-experienced individual (31). One other study performed
245 deep sequencing using Illumina on HBV clones (8), revealing that RAMs S106C, H126Y,
246 D134E, M204I/V & L269I were predominant. Only one study reported sequencing the whole
247 HBV genome, but this was undertaken following i*n vitro* introduction of RAMs into a clinically
248 isolated virus (32), so does not provide any evidence of the association between TFV RAMs
249 and other polymorphisms that might arise on the same viral haplotype.
250
251 **Duration of therapy and treatment compliance prior to detection of tenofovir resistance**
252 Five studies reported the duration in which individuals were on TFV prior to treatment failure,
253 with virological breakthrough occurring between 48 weeks and 48 months of therapy (48
254 weeks (20), 18 months (22), 20 months (29), 26 months (8), and 48 months (7,21)).
255 Compliance was assessed in six studies, among which virological breakthrough despite good
256 treatment compliance was reported in five (8,20,22,29,30), and one reported concerns with
257 compliance (24). Quantification of drug levels in plasma supported good compliance in two
258 studies (8,29).
259
260 **Comparison between HIV and HBV RT**
261 HBV RT has been classified into subdomains which are further divided into regions A – G (36),
262 which form the main catalytic core of the enzyme (Fig 1). Alignment of sequences of HBV and
263 HIV RT demonstrates 25-27% homology between HBV and the HXB2 HIV reference

264 sequence (Fig 2). Comparing sites that have been reported in association with drug resistance
265 in HBV vs HIV (Fig 3, **Suppl Table 5**), we found that among our long-list of 37 HBV RAMs,
266 two sites had identical substitutions in HIV RT (M204 and L229 in HBV (9,11), corresponding
267 to M184 and L210 in HIV, respectively [https://hivdb.stanford.edu/dr-summary/resistance-
268 notes/NRTI/], Fig 3). Other sites reporting an association with TVF resistance in HBV have
269 substitutions that overlap with HIV RAMs, but not all of these are associated with TFV
270 resistance, **Suppl Table 5**.
271
272 Six established TFV RAMs in HIV RT (M41L, K65R, K70E, Y115F, Q151M and T215F/Y) (18)
273 do not correspond to an equivalent mutation in HBV RT, although three of these HIV RAMs
274 have an HBV RAM within 3 amino acids up- or down-stream in the equivalent sequence,
275 suggesting there may be homology in the mechanism through which drug resistance is
276 mediated.
277
278 We mapped HBV RAMs onto the crystal structure of the likely structurally-related HIV RT (pdb
279 code 3dlk) in order to visualise their approximate 3D locations and infer possible functional
280 consequences (Fig 4) (**Suppl Table 6**). The RAMs are primarily located within the 'fingers',
281 'palm', 'thumb' and 'connection' subdomains of the p66 polymerase domain of HIV RT, with
282 the majority within the 'palm'. A number of RAMs (e.g. V207, M204, F249) are spatially
283 adjacent to the catalytically critical (and highly conserved) residues D110, D185 and D186 in
284 HIV RT (D83, D204 and D205 in HBV), suggesting that these RAMs are highly likely to
285 affected catalytic competency. Twenty-two HBV RAMs map to HIV RT residue positions
286 which, if mutated, are likely to cause polymerase structure destabilisation, suggesting that
287 many of these RAMs are likely to impact upon resistance.
288

289 ## DISCUSSION

290 ### Summary of key findings

291 TFV is a safe and effective treatment choice for CHB in the majority of cases, and large case
292 series have not raised significant concerns about clinically significant drug resistance.
293 However, it is important to consider the potential for the emergence of resistance,
294 demonstrated by persistent viraemia on therapy and/or reduced virologic suppression *in vitro*.
295 Based on existing evidence, TFV resistance seems likely to depend on the selection of suites
296 of mutations (most commonly including L180M, A181V/T, M204I/V and/or N236T),
297 overlapping with RAMs that allow escape from other NA drugs. There is also a suggestion
298 that, rarely, single mutations can confer TFV resistance, best demonstrated for S78T.
299
300 Notably, the literature to date is limited and heterogenous, and there remains a lack of
301 evidence about the frequency and likely impact of proposed TFV RAMs either within individual
302 patients or at population level. At present, we have tackled this uncertainty by dividing our
303 catalogue of polymorphisms into a 'long-list' (all reported RAMs) and a 'short-list' (RAMs with
304 the best evidence-base of support).
305
306 Tools that have been designed to identify drug resistance may bias against detection of
307 relevant mutations if they do not scrutinise all relevant sites that contribute to reducing TFV
308 susceptibility. For example, 'TRUGENE' captures common HBV RAMs but does not include
309 positions 78, 177, or 249 which may be pertinent to TFV resistance (37) and 'geno2pheno
310 hbv' only lists one TFV mutation at position 236.
311
312 **Overlap of TFV RAMs with RAMs to other NA agents**
313 RAMs L180M, M204I/V and A181T/V have been associated with resistance to 3TC, LdT and
314 ETV (3,38–41); their reported association with TFV resistance is of concern in suggesting that
315 prior NA exposure can increase the likelihood of cross-resistance to TFV. A study of HIV/HBV
316 co-infected individuals demonstrated a decreased likelihood of HBV DNA suppression with
317 TDF among individuals exposed to prolonged 3TC treatment, possibly due to accumulation of
318 such mutations (42). A large study in China reported A181 and/or N236 substitutions in 11%

319 of the population (40), which may underpin reduced susceptibility to TFV. The structural
320 similarities between ADV and TFV, and similar interaction with HBV polymerase (1,2) explain
321 why the ADV RAMs A181T/V and N236T are also reported to confer resistance to TFV (1,43).
322
323 Although TFV has been considered effective in the context of resistance to other NAs (44),
324 the current evidence suggests that there may be common pathways to resistance (45). There
325 is some evidence showing co-location of RAMs conferring resistance to different antiviral
326 agents on the same viral haplotype (46). These findings suggesting cross-resistance are of
327 concern, especially for settings in which there has been widespread use of NA therapy as a
328 component of ART for HIV (3).
329
330 **Sites of TFV RAMs in HBV RT**
331 Resistance to TFV can be explained by RAMs both within and outside the active site of the
332 RT enzyme, some of which may have similar mechanisms to those described in HIV (9,36).
333 The mechanism of resistance in most of these polymorphisms remains unknown, but may
334 interfere with drug access to sites of activity through steric hindrance. Mutations within active
335 sites of the enzyme may be associated with a higher fitness cost to the virus than mutations
336 at other locations in the RT sequence, as they are more likely to interfere with the RT function.
337 Some polymorphisms listed as RAMs may in fact represent compensatory mutations, that are
338 co-selected in the presence of primary RAMs. For example, substitution at position 269 has
339 been previously described as a compensatory mutation that restores impairments to RT
340 function (47).
341
342 Currently, HBV genotyping is not routinely undertaken in clinical practice, so it is difficult to
343 amass data for any potential relationship between resistance and viral genotype. However,
344 there are some clues that genotype may be relevant. For example, C256S has been linked to
345 TFV resistance, but S256 is wild type in genotype C, **(Suppl Table 4)**, suggesting that the
346 genetic barrier to TFV resistance in genotype C might be lower than in other genotypes.

347 However, a study of >1000 individuals in China found no differences in drug resistance rates
348 between Geno-B vs Geno-C infection (40). The identification of Y9H as a TFV RAM should
349 be viewed with caution as H9 is frequently the wildtype residue, irrespective of genotype.
350
351 **Other factors associated with persistent vireamia**
352 In addition to RAMs, there are other explanations for incomplete suppression of HBV viraemia
353 on therapy (23,31), including a higher baseline HBV DNA level, positive baseline HBeAg
354 status, history of 3TC exposure, a lower nadir CD4+ T cell count in the context of HIV
355 coinfection, and high serum HBV RNA levels (42,48,49). Given that HBV DNA is inhibited in
356 a dose-dependent manner (2), it is also possible that insufficient drug delivery to the infected
357 hepatocyte could be the cause of persistent viraemia even in the absence of specific RAMs.
358
359 Incomplete adherence to therapy can also contribute to virological breakthrough (50). Two
360 studies included in our review assessed treatment compliance by measuring drug
361 concentration in plasma (8,29). Assessment of adherence in chronic HBV has been through
362 the use of questionnaires (51), but these are subject to self-reporting bias. Evidence of
363 potential TFV resistance may emerge when individuals with HIV/HBV coinfection are treated
364 with a TFV-containing regimen leading to suppression of HIV but with sustained HBV vireamia
365 (52).
366
367 It has been reported to take three years for 90% of HBV infected individuals to reach viraemic
368 suppression on therapy (53), in contrast to HIV, in which 88% of patients suppress the virus
369 within the first year of TDF-based treatment (54). In the studies we have reported in this
370 review, persistent HBV viraemia on therapy could be due to the prolonged timeline for viraemic
371 suppression; however, in most studies there was a reduction in viral load when TDF was
372 initiated, with subsequent virological breakthrough that is more in keeping with the selection
373 of resistance.
374

375 **Implications for patient management**

376 There are not currently sufficient data about TFV RAMs to underpin robust universal
377 guidelines for clinical practice. However, the evidence that we have gathered here can
378 underpin some practical recommendations:

379 i. There is an urgent need for more HBV sequencing data, together with
380 contemporaneous viral load measurements and clinical metadata to advance
381 understanding of the relationship between viral sequence and treatment outcomes.
382 Sequence repositories, databases and tools for sequence analysis should regularly
383 review the evidence for TDF RAMs in order to highlight all sites that may be significant
384 in mediating resistance.

385 ii. In the context of failure of viraemic suppression in a patient prescribed therapy,
386 assessing and supporting drug compliance is crucial, ideally together with viral
387 sequencing.

388 iii. Therapeutic failure of TFV – whether in the presence or absence of known RAMs –
389 should lead to an expert clinical decision about switching therapy or combining agents.
390 The presence of recognised RAMs, especially when in combination, may support a
391 change of therapy, considering ETV or combination therapy, although guidance and
392 options are currently limited.

393 iv. If there is an ongoing emergence of data to suggest TFV resistance, there will be a
394 need for expert guidelines to include practical recommendations in order to unify
395 clinical approaches. HIV guidelines should take an active stance on incorporating
396 recommendations for those with HBV co-infection, particularly if dual therapy regimens
397 are adopted.

398 v. Evidence of TFV resistance highlights the need for development of robust novel direct
399 acting antivirals and immune therapies for HBV.

400

401 **Caveats and limitations**

402 There is sparse literature on HBV resistance to TFV, and studies are of varying quality. While
403 there is a high genetic barrier to selection of TFV resistance, it is likely that there is under-
404 reporting of cases of resistance, particularly in low/middle income settings in which routine
405 monitoring of HBV VL on treatment is not undertaken. It can be difficult to infer the impact of
406 common polymorphisms on drug resistance phenotype; for example, it is plausible that
407 M204I/V may be enriched among TFV resistant strains simply as a 'footprint' of prior exposure
408 to 3TC.
409
410 Most studies to date have used Sanger sequencing, and it is possible that significant minority
411 variants may be under-represented, as suggested by one report in which phenotypic TFV
412 resistance was associated with RAMs in <20% of minor variants (31). Low HBV DNA viral
413 loads are a further barrier to sequencing, and bias existing data towards samples from
414 individuals with high viral loads, in which the full spectrum of relevant RAMs may not occur. It
415 is therefore important to invest in deep sequencing platforms that offer the opportunity to
416 explore the full landscape of HBV variants isolated from an infected individual, and to improve
417 sensitivity of sequencing methods including both Sanger and 'next-generation' approaches.
418 Some sequencing methods, such as Oxford Nanopore Technologies, can generate long reads
419 that allow reconstruction of complete viral haplotypes, providing improved certainty about
420 linkages between sites (55). To be able to undertake an appropriate haplotypes analysis would
421 require datasets with robustly phenotyped patients (displaying clinical evidence of drug
422 resistance) together with full length viral sequence data; such datasets have not been
423 generated to date but are an important long-term aim.
424
425 We recognise the limitations of drawing direct comparisons between HIV and HBV RT, given
426 the limited (<30%) sequence homology between the two enzymes, and the finding that only
427 2/37 sites associated with TVF resistance in HBV are homologous RAMs in HIV. This
428 highlights a need for future work to solve the crystal structure of HBV RT.
429

430 **Conclusions**

431 We have assimilated emerging evidence for HBV polymorphisms that reduce susceptibility to
432 TFV, also acknowledging the potential influences of other viral and host factors in cases of
433 persistent viraemia on therapy. While the genetic barrier to resistance is high, evidenced by
434 the large number of mutations that typically have to be selected to produce resistance, of
435 concern is the overlap with other NA resistance mutations, and the instances in which
436 individual amino acid polymorphisms may be sufficient to produce phenotypic resistance.
437 Enhanced studies representing larger numbers of patients, tracking longitudinal viral
438 sequence changes, and monitoring viral suppression over time are needed. In addition, the
439 evolution of better *in vitro* models will support experiments to investigate the effect of individual
440 and combined RAMs. In order to optimise the use of NA therapy as a tool in driving
441 advancements towards elimination at a population level, improved insights into drug
442 resistance are essential. If resistance emerges as a substantial clinical problem, there will be
443 a need for consideration of synergistic drug regimens, new agents that inhibit a target other
444 than viral RT, and for the development of new therapeutic strategies that can bring about cure.
445
446

FINANCIAL SUPPORT STATEMENT: This work was supported by the Leverhulme Mandela Rhodes Scholarship to JM, Wellcome Trust (grant number 110110/Z/15/Z to PCM), the Medical Research Council UK to EB, the Oxford NIHR Biomedical Research Centre to EB. EB is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health.

AUTHORS CONTRIBUTIONS: JM and PCM conceived the study. JM performed literature review. JM, PAB, BDM, PCM analysed the data. JM and PCM wrote the manuscript. All authors revised and approved the final manuscript.

CONFLICT OF INTEREST STATEMENT: We have no conflicts of interest to declare.

TRANSPARENCY DECLARATION: Nothing to declare.

461 **REFERENCES**

462 **1.** Beloukas A, Geretti AM. Hepatitis B Virus Drug Resistance. In: Antimicrobial Drug
463 Resistance. Cham: Springer International Publishing; 2017. p. 1227–42.
464 **2.** Delaney WE, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of
465 tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50(7):2471–
466 7.
467 **3.** Mokaya J, McNaughton AL, Hadley MJ, et al. A systematic review of hepatitis B virus
468 (HBV) drug and vaccine escape mutations in Africa: A call for urgent action. PLoS
469 Negl Trop Dis. 2018;12(8):e0006629.
470 **4.** Warner N, Locarnini S. Mechanisms of hepatitis B virus resistance development.
471 Intervirology. 2014;57(3–4):218–24.
472 **5.** Lee Y Bin, Lee J-H. Is tenofovir monotherapy a sufficient defense line against multi-
473 drug resistant hepatitis B virus? Clin Mol Hepatol. 2017 Sep; 23(3): 219–221.
474 **6.** Zoulim F, Locarnini S. Hepatitis B Virus Resistance to Nucleos(t)ide Analogues.
475 Gastroenterology. 2009;137(5):1593-1608.e2.
476 **7.** Cho WH, Lee HJ, Bang KB, et al. Development of tenofovir disoproxil fumarate
477 resistance after complete viral suppression in a patient with treatment-naive chronic
478 hepatitis B: A case report and review of the literature. World J Gastroenterol. 2018
479 May;24(17):1919–24.
480 **8.** Park E-S, Lee AR, Kim DH, et al. Identification of a quadruple mutation that confers
481 tenofovir resistance in chronic hepatitis B patients. J Hepatol. 2019;70(6):1093-1102.
482 **9.** Das K, Xiong X, Yang H, et al. Molecular Modeling and Biochemical Characterization
483 Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine
484 (3TC) and Emtricitabine (FTC). J Virol. 2001;75(10):4771–9.
485 **10.** Ghany M, Liang TJ. Drug Targets and Molecular Mechanisms of Drug Resistance in
486 Chronic Hepatitis B. Gastroenterology. 2007;132(4):1574-85.

487 **11.** Daga PR, Duan J, Doerksen RJ. Computational model of hepatitis B virus DNA
488 polymerase: molecular dynamics and docking to understand resistant mutations.
489 Protein Sci. 2010;19(4):796–807.
490 **12.** O'Hara GA, McNaughton AL, Maponga T, et al. Hepatitis B virus infection as a
491 neglected tropical disease. PLoS Negl Trop Dis. 2017 Oct 5;11(10):e0005842.
492 **13.** Critical Appraisal Tools - JBI: http://joannabriggs.org/research/critical-appraisal-
493 tools.html
494 **14.** Non-randomised EIG, Longitudinal OC. Appendix B The adapted Quality
495 Assessment Tool for Quantitative Studies (QATQS) Section A -Selection Bias (
496 paper level) Section B – Study Design (paper level) Section C – confounding
497 Section D – Blinding This section is incorporated in section B stu. :4–6.
498 **15.** HIV Databases. https://www.hiv.lanl.gov/content/index
499 **16.** Hayer J, Jadeau F, Deléage G, Kay A, Zoulim F, Combet C. HBVdb: A knowledge
500 database for Hepatitis B Virus. Nucleic Acids Res. 2013 Jan 1;41(D1).
501 **17.** Katoh K, Rozewicki J, Yamada KD. MAFFT online service: multiple sequence
502 alignment, interactive sequence choice and visualization. Brief Bioinform. 2017
503 **18.** Soo-Yon Rhee, Matthew J. Gonzales, Rami Kantor, Bradley J. Betts, Jaideep
504 Ravela, and Robert W. Shafer (2003) Human immunodeficiency virus reverse
505 transcriptase and protease sequence database. Nucleic Acids Res. 2003. 31(1), 298-
506 303.
507 **19.** Sarafianos SG, Marchand B, Das K, et al. Structure and Function of HIV-1 Reverse
508 Transcriptase: Molecular Mechanisms of Polymerization and Inhibition. J Mol Biol.
509 2009;385(3):693–713.
510 **20.** Lee HW, Chang HY, Yang SY, et al. Viral evolutionary changes during tenofovir
511 treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy. J Clin
512 Virol. 2014;60(3):313–6.
513 **21.** Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, et al. Selection of the highly
514 replicative and partially multidrug resistant rtS78T HBV polymerase mutation during

515 TDF-ETV combination therapy. J Hepatol. 2017;67(2):246–54.
516 **22.** Lu J-C, Liu L-G, Lin L, et al. Incident hepatocellular carcinoma developing during
517 tenofovir alafenamide treatment as a rescue therapy for multi-drug resistant hepatitis
518 B virus infection: A case report and review of the literature. World J Clin cases.
519 2018;6(13):671–4.
520 **23.** Schirmer P, Winters M, Holodniy M. HIV-HBV vaccine escape mutant infection with
521 loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine
522 without antiviral resistance. J Clin Virol. 2011;52(3):261–4.
523 **24.** Mikulska M, Taramasso L, Giacobbe DR, et al. Case report: management and HBV
524 sequencing in a patient co-infected with HBV and HIV failing tenofovir. J Med Virol.
525 2012;84(9):1340–3.
526 **25.** Liu Y, Miller MD, Kitrinos KM. HBV clinical isolates expressing adefovir resistance
527 mutations show similar tenofovir susceptibilities across genotypes B, C and D. Liver
528 Int. 2014;34(7):1025–32.
529 **26.** Amini-Bavil-Olyaee S, Herbers U, Sheldon J, et al. The rtA194T polymerase mutation
530 impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive
531 and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology.
532 2009;49(4):1158–65.
533 **27.** Qin B, Budeus B, Cao L, et al. The amino acid substitutions rtP177G and rtF249A in
534 the reverse transcriptase domain of hepatitis B virus polymerase reduce the
535 susceptibility to tenofovir. Antiviral Res. 2013;97(2):93–100.
536 **28.** van Bommel F, Trojan J, Deterding K, et al. Evolution of adefovir-resistant HBV
537 polymerase gene variants after switching to tenofovir disoproxil fumarate
538 monotherapy. Antivir Ther. 2012;17(6):1049–58.
539 **29.** Lada O, Gervais A, Branger M, et al. Quasispecies analysis and in vitro susceptibility
540 of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to
541 tenofovir. Antivir Ther. 2012;17(1):61–70.

542 **30.** Sheldon J, Camino N, Rodés B, et al. Antiviral Therapy 10:727-734 Selection of
543 hepatitis B virus polymerase mutations in HIV-coinfected patients treated with
544 tenofovir. Antiviral Therapy. 2005;10:727–734.
545 **31.** Audsley J, Bent SJ, Littlejohn M, et al. Effects of long-term tenofovir-based
546 combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent
547 hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
548 AIDS. 2016;30(10):1597–606.
549 **32.** Liu Y, Miller MD, Kitrinos KM. Tenofovir alafenamide demonstrates broad cross-
550 genotype activity against wild-type HBV clinical isolates and maintains susceptibility
551 to drug-resistant HBV isolates in vitro. Antiviral Res. 2017 Mar;139:25–31.
552 **33.** Kim HJ, Cho YK, Jeon WK, et al. Clinical characteristics of patients with chronic
553 hepatitis B who developed genotypic resistance to entecavir: Real-life experience.
554 Clin Mol Hepatol. 2017;23(4):323–30.
555 **34.** Fourati S, Rodriguez C, Hézode C, et al. Frequent Antiviral Treatment Failures in
556 Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. Hepatology
557 [Internet]. 2019;69(2):513–23.
558 **35.** Davis C, Mgomella GS, da Silva Filipe A, et al. Highly Diverse Hepatitis C Strains
559 Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting
560 Antiviral Treatments. Hepatology. 2019;69(4):1426–41.
561 **36.** Clark DN, Hu J. Hepatitis B Virus Reverse Transcriptase – Target of Current Antiviral
562 Therapy and Future Drug Development. Antiviral Res. 2015;123:132-7.
563 **37.** Neumann-Fraune M, Beggel B, Kaiser R, et al. Hepatitis B Virus Drug Resistance
564 Tools: One Sequence, Two Predictions. Intervirology. 2014;57(3–4):232–6.
565 **38.** Yatsuji H, Noguchi C, Hiraga N, et al. Emergence of a novel lamivudine-resistant
566 hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob
567 Agents Chemother. 2006;50(11):3867–74.
568 **39.** Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: Mechanisms, detection
569 and interpretation. AIDS.2016; 30(10)1597-1606.

570 **40.** Meng T, Shi X, Gong X, et al. Analysis of the prevalence of drug-resistant hepatitis B
571 virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre
572 (2010–2014). J Glob Antimicrob Resist. 2017;8:74–81.
573 **41.** Hermans LE, Svicher V, Pas SD, et al. Combined analysis of the prevalence of drug-
574 resistant Hepatitis B virus in antiviral therapy-experienced patients in Europe
575 (CAPRE). J Infect Dis. 2016;213(1):39–48.
576 **42.** Kim HN, Rodriguez C V, Van Rompaey S, Eron JJ, Thio CL, Crane HM, et al.
577 Factors associated with delayed hepatitis B viral suppression on tenofovir among
578 patients coinfected with HBV-HIV in the CNICS cohort. J Acquir Immune Defic Syndr.
579 2014;66(1):96–101.
580 **43.** Nidhi G, Milky G, H. WC, et al. The Molecular and Structural Basis of HBV-resistance
581 to Nucleos(t)ide Analogs. J Clin Transl Hepatol. 2014;2(3):202–11.
582 **44.** Lim Y-S. Management of Antiviral Resistance in Chronic Hepatitis B. Gut Liver.
583 2017;11(2):189–95.
584 **45.** Hemert FJ van, Berkhout B, Zaaijer HL. Differential Binding of Tenofovir and Adefovir
585 to Reverse Transcriptase of Hepatitis B Virus. PLoS One. 2014;9(9).
586 **46.** Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus
587 during sequential therapy. Hepatology. 2006;44(3):703–12.
588 **47.** Ahn SH, Kim DH, Lee AR, et al. Substitution at rt269 in Hepatitis B Virus Polymerase
589 Is a Compensatory Mutation Associated with Multi-Drug Resistance. PLoS One.
590 2015;10(8):e0136728.
591 **48.** Hu J, Liu K. Complete and Incomplete Hepatitis B Virus Particles: Formation,
592 Function, and Application. Viruses. 2017;9(3).
593 **49.** Matthews G V, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, et al.
594 Patterns and causes of suboptimal response to tenofovir-based therapy in individuals
595 coinfected with HIV and hepatitis B virus. Clin Infect Dis. 2013 May;56(9):e87-94.
596 **50.** Boyd A, Gozlan J, Maylin S, et al. Persistent viremia in human immunodeficiency
597 virus/hepatitis B coinfected patients undergoing long-term tenofovir: Virological and

598 clinical implications. Hepatology. 2014;60(2):497–507.
599 **51.** Giang L, Selinger CP, Lee AU. Evaluation of adherence to oral antiviral hepatitis B
600 treatment using structured questionnaires. World J Hepatol. 2012;4(2):43.
601 **52.** Maponga TG, McNaughton AL, Schalkwyk M Van, et al. Treatment advantage in
602 HBV/HIV coinfection compared to HBV monoinfection in a South African cohort.
603 medRxiv. 2019;19007963.
604 **53.** Price H, Dunn D, Pillay D, et al. Suppression of HBV by tenofovir in HBV/HIV
605 coinfected patients: a systematic review and meta-analysis. PLoS One.
606 2013;8(7):e68152.
607 **54.** World Health Organisation. Dolutegravir (DTG) and the fixed dose combination
608 (FDC) of tenofovir/lamivudine/dolutegravir (TLD). 2018.
609 https://www.who.int/hiv/topics/treatment/dtg-tld-briefing-web/en/index5.html
610 **55.** McNaughton AL, Roberts HE, Bonsall D, et al. Illumina and Nanopore methods for
611 whole genome sequencing of hepatitis B virus (HBV). Sci Rep. 2019;9(1):7081.
612
613

614 **TABLES**

615 **Table 1: Mutations most commonly reported in association with tenofovir resistance in**
616 **HBV, identified from a systematic literature review.** This table reports a 'short-list' of
617 mutations identified in two or more different studies (7,8,20,24–26,28–30,32). The colour
618 indicates the method(s) used to determine drug resistance. All positions are in HBV RT, listed
619 in numerical order. The 'long-list' of 37 mutations identified in 15 included studies is reported
620 in Suppl Table 3.

621

Mutations	Park et al 2019	Cho et al 2018	Lee et al 2014	Mikulska et al 2012	Liu et al 2014	Amini-Bavil-Olyaee et al 2009	Van Bommel et al 2012	Lada et al 2012	Sheldon et al 2005	Liu et al 2017	Total number of studies	Associated with 3TC resistance	Associated with ETV resistance
S106C/G	(iii)	(i)									2	No	No
R153W/Q			(i)					(iii)			2	No	No
V173L				(i)				(iii)			2	Yes	Yes
L180M			(i)	(i)				(iii)	(iii)		4	Yes	Yes
A181T/V					(ii)		(i)	(iii)		(ii)	4	Yes	Yes
A194T						(ii)			(iii)		2	No	No
M204I/V	(iii)		(i)	(i)				(iii)	(iii)		5	Yes	Yes
N236T					(ii)		(i)			(ii)	3	No	No
I269L	(iii)	(i)									2	No	Yes

KEY:	Method used to identify TFV resistance
(i)	Sequencing HBV sequence from individuals in whom viraemia was not suppressed by TDF
(ii)	In vitro assays to measure the effect of TDF on viral replication in cell lines
(iii)	Approaches (i) and (ii) in combination

622

623

624

625 **FIGURES AND FIGURE LEGENDS**



Enzyme conserved catalytic core	RAMs associated with TDF/TAF located within active sites
A (rt75 – rt91)	S78T; L80M;L91I
B (rt163 – rt189)	I63V; V173L; P177G; **L180M**; **A181T/V**; T184A/L
C (rt200 – rt210)	A200V; **M204I/V**; V207L
D (rt230 – rt241)	**N236T**
E (rt247 – rt257)	F249A; C256S
F(rt37 – rt47)	Nil known
G (rt26 – rt36) &	Nil known

Enzyme domains	RAMs associated with TDF/TAF located within active sites
Finger (rt1 – 54)	Y9H
Palm (rt55 – 104)	**S106C/G**
Finger (rt105 – 169)	T118C/G; F122L; H126Y; Q130S; D134E; **R153W/Q**
Palm (rt170 – 264)	V191I; R192P; **A194T**; L217R; F221Y; S223A; L229V/W; D263E
Thumb (rt265-344)	Q267L; **I269L**; V278I/V; A317S; K333Q; N337H

626

627 **Fig 1: Mutations associated with tenofovir (TFV) resistance located within and outside**
628 **the active sites of the HBV RT enzyme.** Polymerase numbering shown in the grey bars is
629 based on genotype A sequence (accession number X02763). Yellow bar represents RT; green
630 bars represent subdomains which are designated finger, palm and thumb; orange rectangles
631 represent active sites of the enzyme referred to as regions A-G. Mutations associated with
632 TFV resistance (n=37 sites) are listed according to their location within active sites of the
633 enzyme (orange table) or outside active sites (green table). The sites shown in bold represent
634 the nine mutations in our short-list with best literature support (evidence summarised in Table
635 1). Note that in most cases, individual mutations are unlikely to be sufficient to mediate
636 resistance, and a resistant phenotype arises only as a result of combinations of ≥2
637 polymorphisms.



Fig 2: Heatmap showing identity comparison matrix of reference sequence alignment of HBV RT and HIV RT. Chart shows a comparison based on sequences downloaded from HIV sequence database (https://www.hiv.lanl.gov/) and Hepatitis B Virus Database (https://hbvdb.ibcp.fr/HBVdb/) and aligned using MAFFT version 7. HIV reference sequence is HIV HXB2 (K03455). HBV reference sequences are Geno A – FJ692557, Geno B - GU815637, Geno C – GQ377617, Geno D - KC875277, Geno E - GQ161817.

HBV SEQUENCE POSITION	201	202	203	204	205	206	207	208	209	210	211	212		213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233
HBV_Geno_A1	F	S	Y	M	D	D	V	V	L	G	A	K	-	S	V	Q	H	L	E	S	L	Y	T	A	V	T	N	F	L	L	S	L	G	I
HBV_Geno_B2	F	S	Y	M	D	D	V	V	L	G	A	K	-	S	V	Q	H	L	E	S	L	Y	A	A	V	T	N	F	L	L	S	L	G	I
HBV_Geno_C2	F	S	Y	M	D	D	V	V	L	G	A	K	-	S	V	Q	H	L	E	S	L	F	T	S	I	T	N	F	L	L	S	L	G	I
HBV_Geno_D1	F	S	Y	M	D	D	V	V	L	G	A	K	-	S	V	Q	H	L	E	S	L	F	T	A	V	T	N	F	L	L	S	L	G	I
HBV_Geno_E	F	S	Y	M	D	D	V	V	L	G	A	K	-	S	V	Q	H	L	E	S	L	Y	T	S	V	T	N	F	L	L	S	L	G	I
HBV TDF mutation hotspots				M204I/V			V207L											L217R				F221Y		S223A						L229V/W				
HIV SEQUENCE POSITION	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214
HIV_Subtype_B	Y	Q	Y	M	D	D	L	Y	V	G	S	D	L	E	I	G	Q	H	R	T	K	I	E	E	L	R	Q	H	L	L	R	W	G	L
HIV TDF mutation hotspots				M184I/V																										L210W				
Sites with same AA when comparing HIV and HBV RT after alignment			*	*	*	*				*																			*	*			*	

Fig 3: A section of the reference sequence alignment of HBV RT and HIV RT. Sequences downloaded from HIV sequence database at https://www.hiv.lanl.gov/ and Hepatitis B Virus Database at https://hbvdb.ibcp.fr/HBVdb/. Sequences were aligned using MAFFT version 7. HIV subtype B reference sequence is shown in light green (accession number K03455). HBV reference sequences are shown in yellow (Geno-A: FJ692557; Geno-B: GU815637; Geno-C: GQ377617; Geno-D: KC875277; Geno-E: GQ161817). Sites of TFV resistance are highlighted in red, based on the data assimilated in this study. HIV tenofovir RAMs were obtained from the online Stanford Database https://hivdb.stanford.edu/dr-summary/resistance-notes/NRTI/. Sites marked * have the same amino acid in HIV and HBV RT after alignment, and those coloured blue also share TFV resistance mutations. This section is shown as it contains the only two homologous TFV RAMs that we have identified using this approach. Sequence alignments and RAMs throughout the whole RT protein is shown in Suppl Table 5. Note that in most cases, individual mutations are unlikely to be sufficient to mediate resistance, and a resistant phenotype arises only as a result of combinations of ≥2 polymorphisms.



662

663

664 **Fig 4: Cartoon to show the sites of TFV drug resistance polymorphisms, using the**
665 **homologous crystal structure of HIV RT as a model.** The sequence alignment of HBV was
666 extended with HIV RT's p66 domain and then projected onto a high-resolution HIV RT
667 structure (pdb code 3dlk). Sub-domains of the HIV RT are coloured and annotated. Positions
668 associated with resistance are scattered primarily throughout the finger and palm subdomains
669 of the p66 domain (purple space-filled representations, left whole-molecule view, purple stick
670 representation on the zoomed in view on the right). Three aspartate residues, D83, D205 and
671 D206 (indicated by grey space-filled representation) form the catalytic triad of the enzyme and
672 are shown as a point of reference. Of the 37 sites identified as potential TFV RAMs, 24
673 residues which are visible in the structure are labelled (using HBV numbering). This excludes
674 seven putative HBV mutations at sites which do not have a homologous site in the HIV
675 structure (sites 78, 80, 130, 134, 153, 163 and 256), and six sites which are beyond the end
676 of the sequence of the solved crystal HIV structure (267, 269, 278, 317, 333 and 337). Figure
677 produced using the ICM platform (http://www.molsoft.com/icm_browser.html). Note that in
678 most cases, individual mutations are unlikely to be sufficient to mediate resistance, and a
679 resistant phenotype arises only as a result of combinations of ≥2 polymorphisms.

680 **SUPPLEMENTARY DATA**

681 Supporting datafiles can be accessed on-line using the following link:

682 https://figshare.com/s/7dcfa78cc5ed14094d6f

683 On acceptance of the manuscript for publication, the following permanent DOI will be made

684 available: 10.6084/m9.figshare.8427746.

685

686 **Suppl Fig 1: Pharmacokinetics of tenofovir disoproxil fumarate (TDF), tenofovir**

687 **alafenamide (TAF) and adefovir dipivoxil (ADV).** Orange rectangle represents the gut,

688 showing amount of drug absorbed in mg; yellow rectangle represents plasma, in which TDF

689 and ADV are converted to the active molecules, tenofovir and adefovir respectively. Green

690 rectangle represents hepatocytes where the active drug is incorporated into growing HBV

691 DNA to stop viral replication.

692

693 **Suppl Fig 2:** PRISMA flow diagram to illustrate the identification of studies for inclusion in a

694 systematic review of tenofovir resistance in HBV infection (provided in pdf format).

695

696 **Suppl Table 1: Metadata for 15 studies reporting TDF resistance in HBV infection**

697 identified from a systematic literature review.

698

699 **Suppl Table 2: Quality assessment for 15 studies reporting TDF resistance in HBV**

700 **infection.** Studies identified from a systematic literature review.

701

702 **Suppl Table 3: List of 37 tenofovir RAMs in HBV Reverse Transcriptase (RT) reported**

703 **in 15 studies identified through a systematic literature review** (provided in xls format).

704

705 **Suppl Table 4: List of TFV RAMs in HBV, showing consensus residue at each position**

706 **according to HBV genotype, and genotype-specific resistance where this has been**

707 **reported.** List of RAMs obtained from 12 studies included in the review. HBV reference

708 sequences used are the same as for Fig 1. Grey colour highlights the sites that differ from
709 majority consensus. Ticks represent RAMs situated in sites where there is a difference (at
710 consensus level) between genotype sequences. RAMs are listed with the wild-type amino acid
711 first, followed by the numbered position in RT sequence, and the amino acid substitution that
712 is associated with resistance. TFV = tenofovir, RAMs = resistance associated mutations, HBV
713 = hepatitis B virus.
714
715 **Suppl Table 5: Reference sequence alignment of HBV RT and HIV RT**. Sequences
716 downloaded from HIV sequence database online at https://www.hiv.lanl.gov/ and Hepatitis B
717 Virus Database online at https://hbvdb.ibcp.fr/HBVdb/. Alignment undertaken using MAFFT
718 version 7. HIV subtype B reference sequence is shown in light green (accession number
719 K03455). HBV reference sequences (Geno-A: FJ692557; Geno-B: GU815637; Geno-C:
720 GQ377617; Geno-D: KC875277; Geno-: GQ161817 shown in light yellow. TFV RAMs are
721 highlighted in red. HIV TFV RAMs were obtained from Stanford Database
722 (https://hivdb.stanford.edu/dr-summary/resistance-notes/NRTI/). HBV TFV RAMs were
723 obtained from 12 studies included in the review. Sites with the same amino acid at
724 homologous sites are indicated with asterisks (*); among these sites, those that are also
725 shared TVF RAMs are shaded in light blue.
726
727 **Suppl Table 6: Mapping of RAMs to the HIV RT structure.** RAMs were mapped onto the
728 high-resolution structure of HIV RT to infer their possible functional consequences in terms
729 of structure.
730